Previous close | 106.29 |
Open | 106.66 |
Bid | 106.00 x 1200 |
Ask | 106.35 x 1200 |
Day's range | 105.15 - 106.66 |
52-week range | 89.67 - 121.64 |
Volume | |
Avg. volume | 5,670,939 |
Market cap | 183.79B |
Beta (5Y monthly) | 0.74 |
PE ratio (TTM) | 33.00 |
EPS (TTM) | 3.21 |
Earnings date | 18 Jul 2024 - 22 Jul 2024 |
Forward dividend & yield | 2.20 (2.07%) |
Ex-dividend date | 12 Apr 2024 |
1y target est | 126.69 |
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
PBH vs. ABT: Which Stock Is the Better Value Option?
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.